Arg693

Site Information
GtPAGyGrGrEEyEG SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 6009333
Available spectra: 24 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 )
Disease tissue studied:	colorectal cancer ( 23 , 24 , 27 , 28 , 29 , 30 , 32 , 33 ) , colorectal carcinoma ( 23 , 24 , 27 , 28 , 29 , 30 , 32 , 33 ) , gastric cancer ( 18 ) , lung cancer ( 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 ) , non-small cell lung cancer ( 8 , 9 , 10 , 12 , 13 , 14 , 15 , 16 , 17 , 19 , 20 ) , non-small cell lung adenocarcinoma ( 8 , 9 , 10 , 11 , 12 , 13 , 14 , 16 ) , non-small cell large cell lung carcinoma ( 9 , 12 ) , non-small cell squamous cell lung carcinoma ( 11 , 20 ) , small-cell lung cancer ( 6 , 7 ) , teratoma ( 26 )
Relevant cell line - cell type - tissue:	293 (epithelial) ( 1 ) , A549 (pulmonary) ( 8 , 17 ) , Cal-12T (pulmonary) ( 13 ) , Calu-3 (pulmonary) ( 10 ) , DMS153 (pulmonary) ( 14 ) , DMS53 (pulmonary) ( 7 ) , DMS79 (pulmonary) ( 6 ) , HCC15 (pulmonary) ( 11 ) , HCC44 (pulmonary) ( 13 ) , HCC78 (pulmonary) ( 12 ) , HCC827 (pulmonary) ( 10 ) , HCT116 (intestinal) ( 4 , 21 , 22 , 23 , 24 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 39 , 40 , 41 , 42 ) , HEK293T (epithelial) [PADI4 (human), no information, doxycyline inducible over-expression of PADI4] ( 3 ) , HEK293T (epithelial) ( 3 ) , HeLa S3 (cervical) ( 5 ) , Jurkat (T lymphocyte) ( 2 , 37 , 38 , 43 , 44 , 45 ) , LOU-NH91 (squamous) ( 11 ) , lung ( 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 ) , MKN-45 (gastric) ( 18 ) , NCCIT (epithelial) ( 26 ) , NCI-H128 (pulmonary) ( 6 ) , NCI-H1299 (pulmonary) ( 9 ) , NCI-H1355 (pulmonary) ( 8 ) , NCI-H1417 (pulmonary) ( 6 ) , NCI-H1437 (pulmonary) ( 13 , 14 ) , NCI-H1650 (pulmonary) ( 10 ) , NCI-H1666 (pulmonary) ( 13 ) , NCI-H1703 (squamous) ( 11 , 20 ) , NCI-H1734 (pulmonary) ( 9 ) , NCI-H1781 (pulmonary) ( 12 ) , NCI-H1792 (pulmonary) ( 8 ) , NCI-H1944 (pulmonary) ( 9 ) , NCI-H1975 (pulmonary) ( 10 ) , NCI-H2073 (pulmonary) ( 11 , 14 ) , NCI-H209 (pulmonary) ( 6 , 14 ) , NCI-H2106 (pulmonary) ( 10 ) , NCI-H2228 (pulmonary) ( 12 , 16 ) , NCI-H23 (pulmonary) ( 8 ) , NCI-H2342 (pulmonary) ( 11 ) , NCI-H2405 (pulmonary) ( 13 ) , NCI-H3122 (pulmonary) ( 12 , 15 ) , NCI-H3255 (pulmonary) ( 19 ) , NCI-H358 (pulmonary) ( 9 ) , NCI-H441 (pulmonary) ( 8 ) , NCI-H446 (pulmonary) ( 7 ) , NCI-H460 (pulmonary) ( 9 ) , NCI-H524 (pulmonary) ( 6 ) , NCI-H526 (pulmonary) ( 7 ) , NCI-H661 (pulmonary) ( 12 ) , NCI-H69 (pulmonary) ( 7 ) , NCI-H82 (pulmonary) ( 7 ) , NCI-H838 (pulmonary) ( 14 ) , NT2 (testicular) ( 25 ) , T lymphocyte ( 2 ) , U2OS (bone cell) ( 3 )

References
1	Larsen SC, et al. (2016) Proteome-wide analysis of arginine monomethylation reveals widespread occurrence in human cells. Sci Signal 9, rs9 27577262 Curated Info
2	Geoghegan V, et al. (2015) Comprehensive identification of arginine methylation in primary T cells reveals regulatory roles in cell signalling. Nat Commun 6, 6758 25849564 Curated Info
3	Sylvestersen KB, et al. (2014) Proteomic analysis of arginine methylation sites in human cells reveals dynamic regulation during transcriptional arrest. Mol Cell Proteomics 13, 2072-88 24563534 Curated Info
4	Guo A, et al. (2014) Immunoaffinity enrichment and mass spectrometry analysis of protein methylation. Mol Cell Proteomics 13, 372-87 24129315 Curated Info
5	Bremang M, et al. (2013) Mass spectrometry-based identification and characterisation of lysine and arginine methylation in the human proteome. Mol Biosyst 9, 2231-47 23748837 Curated Info
6	Rikova K (2013) CST Curation Set: 20094; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Antibodies Used to Purify Peptides prior to LCMS: Mono-Methyl Arginine [mme-R] MultiMab(TM) Rabbit mAb mix Cat#: 8015 Curated Info
7	Rikova K (2013) CST Curation Set: 20095; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Antibodies Used to Purify Peptides prior to LCMS: Mono-Methyl Arginine [mme-R] MultiMab(TM) Rabbit mAb mix Cat#: 8015 Curated Info
8	Rikova K (2013) CST Curation Set: 20096; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Antibodies Used to Purify Peptides prior to LCMS: Mono-Methyl Arginine [mme-R] MultiMab(TM) Rabbit mAb mix Cat#: 8015 Curated Info
9	Rikova K (2013) CST Curation Set: 20097; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Antibodies Used to Purify Peptides prior to LCMS: Mono-Methyl Arginine [mme-R] MultiMab(TM) Rabbit mAb mix Cat#: 8015 Curated Info
10	Rikova K (2013) CST Curation Set: 20098; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Antibodies Used to Purify Peptides prior to LCMS: Mono-Methyl Arginine [mme-R] MultiMab(TM) Rabbit mAb mix Cat#: 8015 Curated Info
11	Rikova K (2013) CST Curation Set: 20099; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Antibodies Used to Purify Peptides prior to LCMS: Mono-Methyl Arginine [mme-R] MultiMab(TM) Rabbit mAb mix Cat#: 8015 Curated Info
12	Rikova K (2013) CST Curation Set: 20100; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Antibodies Used to Purify Peptides prior to LCMS: Mono-Methyl Arginine [mme-R] MultiMab(TM) Rabbit mAb mix Cat#: 8015 Curated Info
13	Rikova K (2013) CST Curation Set: 20101; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Antibodies Used to Purify Peptides prior to LCMS: Mono-Methyl Arginine [mme-R] MultiMab(TM) Rabbit mAb mix Cat#: 8015 Curated Info
14	Rikova K (2013) CST Curation Set: 20102; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Antibodies Used to Purify Peptides prior to LCMS: Mono-Methyl Arginine [mme-R] MultiMab(TM) Rabbit mAb mix Cat#: 8015 Curated Info
15	Rikova K (2013) CST Curation Set: 18851; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Antibodies Used to Purify Peptides prior to LCMS: Mono-Methyl Arginine [mme-R] MultiMab(TM) Rabbit mAb mix Cat#: 8015 Curated Info
16	Rikova K (2013) CST Curation Set: 18850; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Antibodies Used to Purify Peptides prior to LCMS: Mono-Methyl Arginine [mme-R] MultiMab(TM) Rabbit mAb mix Cat#: 8015 Curated Info
17	Rikova K (2012) CST Curation Set: 16037; Year: 2012; Biosample/Treatment: cell line, A549/iressa, gleevec, crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Antibodies Used to Purify Peptides prior to LCMS: Mono-Methyl Arginine (Me-R4-100) Rabbit mAb Cat#: 8015 Curated Info
18	Rikova K (2012) CST Curation Set: 16034; Year: 2012; Biosample/Treatment: cell line, MKN45/crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Antibodies Used to Purify Peptides prior to LCMS: Mono-Methyl Arginine [mme-R] MultiMab(TM) Rabbit mAb mix Cat#: 8015 Curated Info
19	Rikova K (2012) CST Curation Set: 16035; Year: 2012; Biosample/Treatment: cell line, H3255/iressa; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Antibodies Used to Purify Peptides prior to LCMS: Mono-Methyl Arginine [mme-R] MultiMab(TM) Rabbit mAb mix Cat#: 8015 Curated Info
20	Rikova K (2012) CST Curation Set: 16036; Year: 2012; Biosample/Treatment: cell line, H1703/gleevec; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Antibodies Used to Purify Peptides prior to LCMS: Mono-Methyl Arginine [mme-R] MultiMab(TM) Rabbit mAb mix Cat#: 8015 Curated Info
21	Mulhern D (2011) CST Curation Set: 13243; Year: 2011; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Antibodies Used to Purify Peptides prior to LCMS: Mono-Methyl Arginine (R*GG) (D5A12) Rabbit mAb Cat#: 8711, PTMScan(R) Mono-Methyl Arginine (D5A12) Immunoaffinity Beads Cat#: 8963 Curated Info
22	Mulhern D (2011) CST Curation Set: 13240; Year: 2011; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Antibodies Used to Purify Peptides prior to LCMS: Mono-Methyl Arginine (Me-R(4)-100) Rabbit mAb Cat#: 8015, PTMScan?(R) Mono-methyl arginine (r) Immunoaffinity Beads Cat#: 8163 Curated Info
23	Possemato A (2010) CST Curation Set: 9753; Year: 2010; Biosample/Treatment: cell line, HCT 116/control; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Antibodies Used to Purify Peptides prior to LCMS: Mono-Methyl Arginine (Me-R(4)-100) Rabbit mAb Cat#: 8015 Curated Info
24	Possemato A (2010) CST Curation Set: 9754; Year: 2010; Biosample/Treatment: cell line, HCT 116/control; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Curated Info
25	Zhou J (2010) CST Curation Set: 9113; Year: 2010; Biosample/Treatment: cell line, NTERA-2/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Curated Info
26	Zhou J (2010) CST Curation Set: 9112; Year: 2010; Biosample/Treatment: cell line, NCCIT/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Curated Info
27	Possemato A (2010) CST Curation Set: 8862; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Curated Info
28	Possemato A (2010) CST Curation Set: 8861; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Curated Info
29	Possemato A (2010) CST Curation Set: 8863; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Curated Info
30	Possemato A (2010) CST Curation Set: 8860; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Curated Info
31	Possemato A (2009) CST Curation Set: 6751; Year: 2009; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Curated Info
32	Possemato A (2009) CST Curation Set: 6001; Year: 2009; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Curated Info
33	Zhou J (2008) CST Curation Set: 5630; Year: 2008; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Curated Info
34	Zhou J (2008) CST Curation Set: 5631; Year: 2008; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Curated Info
35	Zhou J (2008) CST Curation Set: 5632; Year: 2008; Biosample/Treatment: cell line, HCT116/Adox; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Curated Info
36	Zhou J (2008) CST Curation Set: 5633; Year: 2008; Biosample/Treatment: cell line, HCT116/Adox; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Curated Info
37	Possemato A (2008) CST Curation Set: 5343; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Curated Info
38	Possemato A (2008) CST Curation Set: 5344; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Curated Info
39	Zhou J (2008) CST Curation Set: 5147; Year: 2008; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Curated Info
40	Zhou J (2008) CST Curation Set: 5148; Year: 2008; Biosample/Treatment: cell line, HCT116/Adox; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Curated Info
41	Zhou J (2008) CST Curation Set: 5149; Year: 2008; Biosample/Treatment: cell line, HCT116/Adox; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Curated Info
42	Zhou J (2008) CST Curation Set: 5157; Year: 2008; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Curated Info
43	Possemato A (2008) CST Curation Set: 3779; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Curated Info
44	Possemato A (2008) CST Curation Set: 3780; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Curated Info
45	Possemato A (2008) CST Curation Set: 3752; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Curated Info